SiteOne Therapeutics, located in South San Francisco, California, and Bozeman, Montana, is dedicated to the development of novel therapeutics to safely and effectively treat hypersensitivity disorders of the peripheral nervous system, such as chronic cough and chronic pain. The company’s therapeutic candidates are highly selective inhibitors of sodium ion channel isoforms Nav1.7 and Nav1.8. Given the critical role that sodium channels play in the generation and conduction of noxious electrical signals, combined with the urgent need for new, non-opioid therapies for chronic cough and chronic pain, SiteOne is focused on advancing its lead products to serve patients that suffer from these debilitating hypersensitivity disorders.
Contact Us
SiteOne Therapeutics, Inc.
280 Utah Ave., Suite 250
South San Francisco, CA 94080
PO Box 1289
Bozeman, MT 59771-1289
+1 (650) 392-0419
info@site1therapeutics.com